Please login to the form below

Not currently logged in
Email:
Password:

inflammatory disease

This page shows the latest inflammatory disease news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s leukaemia drug Mylotarg backed for use in EU

Pfizer’s leukaemia drug Mylotarg backed for use in EU

Kineret (anakinra) in rare inflammatory condition Still’s disease; and Pfizer’s Bosulif (bosutinib) as a treatment for newly-diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia (CML).

Latest news

  • Shaky mid-stage data won’t halt Celgene’s plans for Otezla Shaky mid-stage data won’t halt Celgene’s plans for Otezla

    Celgene intends to expand its use into a series of other inflammatory diseases with ulcerative colitis at the head of its list along with Behçet’s disease. ... Celgene reported stronger data with Otezla in reducing oral ulcers in patients with

  • J&J takes option on Theravance’s JAK drug in $1bn deal J&J takes option on Theravance’s JAK drug in $1bn deal

    and Crohn’s disease. ... Despite the competition, J&J says TD-1473 has qualities which could make it a better option for inflammatory bowel disease.

  • Novartis joins biosimilar Humira push in US Novartis joins biosimilar Humira push in US

    Sandoz has already filed its Humira biosimilar in the EU, seeking approval as a cheaper alternative to AbbVie's drug in several immunological diseases, including psoriasis, rheumatoid arthritis and inflammatory bowel ... who suffer from an inflammatory

  • CHMP backs Europe’s first allogeneic stem cell therapy CHMP backs Europe’s first allogeneic stem cell therapy

    Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract affecting some 1.6 million people in Europe, and in around a quarter of patients can cause fistulas - abnormal ... With a CHMP green light, that should be forthcoming early

  • Boehringer builds evidence base for its Humira biosimilar Boehringer builds evidence base for its Humira biosimilar

    Biosimilars have potential cost benefits to the healthcare system and support affordable access to important biologic medicines for patients living with inflammatory disease like RA.”. ... That recommendation covered its use to treat adults with

More from news
Approximately 1 fully matching, plus 145 partially matching documents found.

Latest Intelligence

  • The tipping point The tipping point

    In chronic diseases such as rheumatoid arthritis and inflammatory bowel disease, there are significantly greater savings from switching patients compared with initiating biosimilars in naïve patients alone.

  • Taking a lean and careful approach Taking a lean and careful approach

    Its fully human engineered CD3 antibody Foralumab has reached phase II with potential for a wide range of autoimmune and inflammatory diseases such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis, ... ulcerative colitis, type 1

  • Deal Watch February 2017 Deal Watch February 2017

    The deal also includes a licence to AKB-5169 (formerly JNJ5169), an oral, preclinical stage compound for inflammatory bowel disease (IBD). ... Royalty monetisation. 150. BIAL/ Neurocrine Biosciences. ONGENTYS (opicapone), COMT inhibitor for Parkinson's

  • Deal Watch December 2016 Deal Watch December 2016

    510. Nuevolution (Denmark). Almirall (Spain). Research collaboration. RORγt inhibitors for inflammatory skin diseases and psoriatic arthritis. ... inflammatory bowel disease and multiple sclerosis.

  • Deal Watch June 2016 Deal Watch June 2016

    Also out-licensing during June was Pfizer, which granted Shire global rights to a phase 3 ready antibody called PF-00547659 for the treatment of moderate to severe inflammatory bowel disease ... US Centers for Disease Control and Prevention (CDC)).

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics